The Company is also studying P1101 in the single-arm phase 2B EXCEED-ET trial (ClinicalTrials.gov Identifier: NCT05482971) to evaluate the efficacy, safety, and tolerability of P1101 in adult patients ...

The NDA is supported by data from the open-label, single-center phase 1/2 90-CH-0149 trial and the open-label, single-arm phase 3 09-CH-0059 study.

Budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol ...

(HealthDay News)-— The A (H5N1) virus generally causes mild illness of short duration, mainly among US adults exposed to infected animals, according to a study published online Dec. 31 in the New ...

Odds of complications significantly reduced with early anti-TNFα therapy, especially in those with perianal lesions ...

An expert panel consisting of dietitians, doctors, nutritional epidemiologists, chefs, and weight loss researchers examined ...

(HealthDay News) — Vaccines to protect against respiratory syncytial virus (RSV) in newborns and older adults are being more ...

The FDA is expected to decide on treatments for Parkinson disease, PTSD and NF1-associated plexiform neurofibromas, in addition to 2 new vaccines.

Significant reductions seen in birth weight with exposure to certain DMTs, and increase seen in rate of small for gestational age ...

The approval of Opdivo Qvantig was supported by data from the randomized, open-label phase 3 CheckMate-67T study.

Navacaprant is an highly selective kappa opioid receptor antagonist expected to modulate reward processing pathways and mediate depressive states.